ECCMID: Epstein-Barr Virus Associated with Cervical Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




ECCMID: Epstein-Barr Virus Associated with Cervical Cancer

By Eurona Earl Tilley

PRAGUE, CZECH REPUBLIC -- May 10, 2004 -- Epstein-Barr Virus (EBV) may play a key factor in the pathogenesis of cervical cancer, according to a study presented here May 4th at the 14th European Congress on Clinical Microbiology and Infectious Diseases.

Latent membrane protein-1 (LMP-1) of EBV was previously shown to aid in the neoplastic transformation of epithelial cells during both productive and latent infections. Marzena Wal, MSc, Poznan University of Medical Sciences, Poland, sought to examine whether EBV is associated with cervical intraepithelial neoplasia.

Ms. Wal evaluated cervical specimens from 19 women with cervical intraepithelial neoplasia. Ten of these patients with mild dysplasia were classified as Subgroup 1, and 9 patients with moderate dysplasia, severe dysplasia, or carcinoma in situ were classified as Subgroup 2. In addition, Ms. Wal and colleagues evaluated cervical specimens from 26 women free of cervical intraepithelial neoplasia. The age range for the group that was positive for cervical intraepithelial neoplasia was 21 to 42 years. The age range for the control group was 21 to 43 years.

Each cervical specimen was tested for the presence of EBV-DNA and Human Papilloma virus (HPV) deoxyribonucleic acid (DNA) using polymerase chain reaction and enzyme linked immunosorbent assay (ELISA) techniques. The sera of each woman were also tested for antibodies against EBV. Immunoglobulin G (IgG) anti-early antigen, immunoglobulin M and IgG anti-viral capsid antigen and IgG anti-Epstein Barr Nuclear Antigen antibodies were all quantitated by ELISA.

Ms. Wal found that all the women who presented with mild dysplasia were HPV-negative, although 2 of them tested positive for the presence of EBV-DNA. In Subgroup 2, 7 of the women were HPV-16 positive and 2 were negative for HPV-DNA. All of the women in Subgroup 2 tested positive for the presence of EBV-DNA. Each of the women from both subgroups had serum anti-EBV antibodies. Among the control group, 8 women were EBV-DNA positive, 2 were HPV-DNA positive, and 16 had neither the presence of EBV-DNA nor HPV-DNA.

Ms. Wal concluded that there is compelling evidence that EBV is involved in cervical-cancer aetiopathogens. Further studies, she says, are warranted.

[Presentation title: "Epstein-Barr virus (EBV) and cervix uterine cancer." Abstract #P1611]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities